CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension

NDA FilingseralutinibPositive
AI Analysis

Summary

Gossamer Bio has submitted an NDA for seralutinib for the treatment of pulmonary arterial hypertension, advancing the drug toward potential FDA approval.

Importance:7/10
Sentiment:
0.60
NDA submissionpulmonary arterial hypertensionregulatory milestone
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on September 23, 2026 10:16 PM

Read Original